1RVMD Stock Overview

A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. More details

1RVMD fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 86.5% below our estimate of its fair value

Revenue is forecast to grow 66.95% per year

Analysts in good agreement that stock price will rise by 83%

Risk Analysis

Shares are highly illiquid

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Revolution Medicines, Inc. Competitors

Philogen

BIT:PHIL

€910.5m

Moderna

NasdaqGS:MRNA

US$9.6b

Recordati Industria Chimica e Farmaceutica

BIT:REC

€10.6b

Beijing Wantai Biological Pharmacy Enterprise

SHSE:603392

CN¥85.2b

Price History & Performance

Summary of share price highs, lows and changes for Revolution Medicines
Historical stock prices
Current Share Price	US$35.20
52 Week High	US$0
52 Week Low	US$0
Beta	1.11
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	6.67%

Recent updates

Shareholder Returns

	1RVMD	IT Biotechs	IT Market
7D	-2.8%	1.6%	2.9%
1Y	n/a	0.3%	14.1%

Return vs Industry: Insufficient data to determine how 1RVMD performed against the Italian Biotechs industry.

Return vs Market: Insufficient data to determine how 1RVMD performed against the Italian Market.

Price Volatility

Is 1RVMD's price volatile compared to industry and market?
1RVMD volatility
1RVMD Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.4%
Market Average Movement	5.5%
10% most volatile stocks in IT Market	8.7%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1RVMD's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1RVMD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	616	Mark Goldsmith	www.revmed.com

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C).

Revolution Medicines, Inc. Fundamentals Summary

How do Revolution Medicines's earnings and revenue compare to its market cap?
1RVMD fundamental statistics
Market cap	€6.61b
Earnings (TTM)	-€625.59m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-10.6x

P/E Ratio

Is 1RVMD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1RVMD income statement (TTM)
Revenue	US$0
Cost of Revenue	US$679.95m
Gross Profit	-US$679.95m
Other Expenses	US$17.55m
Earnings	-US$697.51m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-3.74
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 1RVMD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/18 18:18
End of Day Share Price	2025/05/16 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Revolution Medicines, Inc. is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Peter Lawson	Barclays
Alec Stranahan	BofA Global Research
Chris Shibutani	Goldman Sachs

Revolution Medicines BIT:1RVMD Stock Report